A 2Â weeks on and 1Â week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

Treatment with sunitinib on schedule 2/1 is associated with significantly decreased toxicity in patients who experience grade 3 or greater toxicity on schedule 4/2, and can extend treatment duration considerably. Prospective clinical trials are required to define the optimal sunitinib schedule to balance efficacy and toxicity.